We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Advanced Liquid Logic Acquires Nanolytics

By Labmedica staff writers
Posted on 12 Mar 2007
Advanced Liquid Logic (Morrisville, NC, USA) a microfluidics "lab-on-a-chip” spinout from Duke University's Pratt School of Engineering (Durham, NC, USA), announced that it has acquired Nanolytics, Inc. More...
The terms of the acquisition were not disclosed.

"This clearly gives us the high ground in the race for both demonstrated progress and intellectual property in this exciting new technology. The technology has huge potential for miniaturizing test equipment and performing complex tests at the point of sample collection,” said Richard West, CEO of Advanced Liquid Logic. "Not only will we benefit from Nanolytics' patents but from the continuing contributions of key Nanolytics employees as well.”

Nanolytics, founded in the late 1990s, received several million dollars in commercial and government support prior to the transaction. Michael Pollack, an early Nanolytics employee, left Nanolytics to further develop the technology at Duke University and then went on to co-found Advanced Liquid Logic in 2004. "Our own excellent team has brought us to this important milestone,” said Advanced Liquid Logic's other co-founder Vamsee Pamula. "While the technology is exciting, it takes much more than that to create a promising company with the resources to become the industry leader.”

Advanced Liquid Logic is leading the development of a new technology for micro-liquid-handling called digital microfluidics. Small droplets can be moved under direct, programmable, software control to perform complex, liquid-based testing in a palmtop-sized device. The company's primary focus is developing products for medical diagnostics and monitoring. The company has demonstrated clinical chemistry assays, immunoassays, and polymerase chain reaction (PCR) on the technology platform and is in the process of implementing DNA sequencing, analyte sorting, test multiplexing, and integrated sample preparation.


Related Links:
Advanced Liquid Logic
Duke University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.